Skip to content

Levofloxacin, Metronidazole, and Lansoprazole Triple Therapy Compared to Quadruple Therapy as a Second-Line Treatment of Helicobacter pylori Infection in Korea

Document Type
Publications · Journal Article
Registered DB
KCISCIEScopus
Journal Ranking
JCR Q4Scopus Q2
Journal
GUT AND LIVER7(4) · pp.406 · 2013
Citation
Web of Science 17KCI 7
JCR IF
JCR 2012 1.314
ISSN
1976-2283

Authors

  1. Moon, Ji YoonFirst author부산대학교
  2. Kim, Gwang-haCorresponding author부산대학교
  3. 유현석부산대학교
  4. Lee, Bong Eun부산대학교
  5. Ryu, Dong Yup부산대학교
  6. Cheong, Jae Hoon부산대학교
  7. 송철수부산대학교
  8. Song, Geun-am부산대학교
  9. Jung, Jung Im부산대학교

Abstract

Background/Aims: Several rescue therapies have been recommended to eradicate Helicobacter pylori infection in patients with a failure of first-line eradication therapy, but they still fail in more than 20% of cases. The aim of this study was to evaluate the efficacy and safety of levofloxacin, metronidazole, and lansoprazole (LML) triple therapy relative to quadruple therapy as a second-line treatment. Methods: In total, 113 patients who failed first-line triple therapy for H. pylori infection were randomly assigned to two groups: LML for 7 days and tetracycline, bismuth subcitrate, metronidazole and lansoprazole (quadruple) for 7 days. Results: According to intention-to-treat analysis, the infection was eradicated in 38 of 56 patients (67.9%) in the LML group and 48 of 57(84.2%) in the quadruple group (p=0.042). Per-protocol analysis showed successful eradication in 38 of 52 patients (73.1%) from the LML group and 48 of 52 (92.3%) from the quadruple group (p=0.010). There were no significant differences in the adverse effects in either treatment group. Conclusions: LML therapy is less effective than quadruple therapy as a second-line treatment for H. pylori infection. Therefore, quadruple therapy should be considered as the primary second-line strategy for patients experiencing a failure of first-line H. pylori therapy in Korea.

Keywords

Helicobacter pyloriTherapeuticsFailureLevofloxacinMetronidazolePROTON-PUMP INHIBITORRESCUE THERAPYTREATMENT FAILURECONTROLLED-TRIALERADICATIONMETAANALYSISCLARITHROMYCINAMOXICILLINMANAGEMENTRESISTANCE

Identifiers

WoS UID
000322057500004
KCI
ART001789282